San Francisco, CA - 2013 Gastrointestinal Cancers Symposium - San Francisco, CA: Fotios Loupakis discusses FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial. during the Oral Abstract Session: Cancers of the Colon and Rectum at the Gastrointestinal Cancers Symposium 2013 here today, Saturday January 26, 2013. The Symposium is supported by ASCO, the American Society of Clinical Oncology, ASTRO, The American Society of Radiation Oncology, SSO, Society of Surgical Oncology and the AGA Institute. Over 3,000 physicians, researchers and allied healthcare professionals are attending the meeting which is being held at the Moscone West center in San Francisco and features the latest Gastrointestinal Cancers research in the areas of basic and clinical science. Date: Saturday January 26, 2013. Photo by © ASCO/Todd Buchanan 2013 Technical Questions: email@example.com; Phone: 612-226-5154.